24 related articles for article (PubMed ID: 38619967)
1. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.
Okamoto T; Yoneyama MS; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C; Tsuboi S
Mol Med Rep; 2013 Feb; 7(2):359-64. PubMed ID: 23165940
[TBL] [Abstract][Full Text] [Related]
2. Secretome analysis identifies novel signal Peptide peptidase-like 3 (Sppl3) substrates and reveals a role of Sppl3 in multiple Golgi glycosylation pathways.
Kuhn PH; Voss M; Haug-Kröper M; Schröder B; Schepers U; Bräse S; Haass C; Lichtenthaler SF; Fluhrer R
Mol Cell Proteomics; 2015 Jun; 14(6):1584-98. PubMed ID: 25827571
[TBL] [Abstract][Full Text] [Related]
3. Metabolic engineering challenges of extending N-glycan pathways in Chinese hamster ovary cells.
Wang Q; Wang T; Yang S; Sha S; Wu WW; Chen Y; Paul JT; Shen RF; Cipollo JF; Betenbaugh MJ
Metab Eng; 2020 Sep; 61():301-314. PubMed ID: 32663509
[TBL] [Abstract][Full Text] [Related]
4. NK Cell Maturation and Cytotoxicity Are Controlled by the Intramembrane Aspartyl Protease SPPL3.
Hamblet CE; Makowski SL; Tritapoe JM; Pomerantz JL
J Immunol; 2016 Mar; 196(6):2614-26. PubMed ID: 26851218
[TBL] [Abstract][Full Text] [Related]
5. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.
Suzuki Y; Sutoh M; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Habuchi T; Arai Y; Fukuda M; Ohyama C; Tsuboi S
Int J Oncol; 2012 Jun; 40(6):1831-8. PubMed ID: 22446589
[TBL] [Abstract][Full Text] [Related]
6. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
7. Viral Evasion of Natural Killer Cell Activation.
Ma Y; Li X; Kuang E
Viruses; 2016 Apr; 8(4):95. PubMed ID: 27077876
[TBL] [Abstract][Full Text] [Related]
8. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of tumor cells escaping from immune surveillance of NK cells.
Ge Z; Wu S; Zhang Z; Ding S
Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
11. Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells.
Zhuang X; Woods J; Ji Y; Scheich S; Mo F; Rajagopalan S; Coulibaly ZA; Voss M; Urlaub H; Staudt LM; Pan KT; Long EO
Cell Rep; 2024 Apr; 43(4):114105. PubMed ID: 38619967
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
